Denovo Biopharma News

Management Advisors Pipeline News Careers Publications Contact Us 中文

News

Current Year

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

2021

Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences

Denovo’s Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma

First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102 (Enzastaurin) in Patients with Newly-Diagnosed Glioblastoma (GBM)

2020

Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics

Denovo Biopharma LLC’s Phase 3 Pivotal ENGINE Study of DB102 (Enzastaurin) in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Is Fully Enrolled

2020/07 FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)

2020/06 Denovo closes $83.5M series C round to support phase III trials of enzastaurin

2020/04 Denovo Biopharma To Acquire Tocagen’s Entire Replicating Gene Therapy Platform and Related Assets

2020/03 Denovo Biopharma Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB104 (Liafensine) for Depression - Potential First Pharmagenomic Biomarker in Neurological Diseases

2020/01 Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

2019

2019/12 Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals

2019/10 Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)

2019/06 Denovo Biopharma Receives Global Rights to a Novel Late-Stage Drug for Alzheimer’s Disease from Orion Corporation for Development as a Personalized Medicine

2019/05 Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML)

2018 and Prior

2018/11 Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting

2018/11 Speedy China IND approval as Denovo takes aim at large schizophrenia market (BioWorld Cover Story)

2018/10 Denovo Biopharma to Participate at Morgan Stanley 17th Annual Asia Pacific Summit

2018/06 Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension

2018/05 Denovo Biopharma to Participate in Jefferies 2018 Global Healthcare Conference

2018/05 Denovo Biopharma to Participate at Morgan Stanley 4th Annual China Summit

2018/04 Denovo kicks off phase III biomarker-driven trial in DLBCL; doses first patient in China (BioWorld Top Line News)

2018/04 First Patient Dosed in Pivotal Biomarker-Guided Phase 3 Study of First Line Therapy with DB102 (enzastaurin) + R-CHOP in Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

2018/01 San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO

About Us

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Network with Us